KAILUA-KONA, Hawaii, March 06, 2018 -- Nutrex Hawaii, Inc. is pleased to announce that its BioAstin® Hawaiian Astaxanthin® and MD Formulas™ have received The International GMO Evaluation and Notification Program™ (IGEN) verification. BioAstin Hawaiian Astaxanthin is a powerful antioxidant supplement derived from natural microalgae grown on the Kona Coast of the Big Island of Hawaii.
“We chose to verify our astaxanthin products with IGEN, because it assures our commitment to consumer trust and transparency,” said Mawae Morton, CEO, Nutrex Hawaii, Inc. “Ensuring that our astaxanthin and other ingredients in our products are natural, non-synthetic, and GMO-free reinforces our dedication to providing high quality microalgae products from natural ingredients and sources to our valued consumers. Non-GMO verified and non-synthetic products are what our consumers want, and we are dedicated to delivering on this expectation. Our consumers seek natural products because synthetic ingredients are often derived from petrochemicals.”
IGEN is a third-party certification program developed to test for the presence of EU classified genetically modified organisms (GMOs), including both proteins and genes. The IGEN programs rigorous standards require that products must contain undetectable amounts of GMO proteins equivalent to <0.1% GMO.
“Our BioAstin Hawaiian Astaxanthin continues to be the only astaxanthin grown and processed in the state of Hawaii. We take great pride in being able to utilize the natural environment around us to effectively grow microalgae and offer a high-quality dietary supplement as a result. In addition to third-party quality testing such as IGEN, BioAstin undergoes rigorous in-house testing for contaminants such as herbicides, pesticides, heavy metals, and identity. Our quality standards ensure that our astaxanthin is some of the cleanest and purest astaxanthin available on the market. We believe our consumers appreciate our commitment and dedication to producing a superior quality and a locally grown product. We thank our customers for continuing to make BioAstin Hawaiian Astaxanthin their number one choice for astaxanthin,” added Morton.
BioAstin Hawaiian Astaxanthin is the top selling brand of astaxanthin in the state of Hawaii and across the entire US mainland.† BioAstin helps support recovery from intense exercise as well as support skin, cardiovascular, and eye health.* BioAstin is also certified gluten-free by the Gluten Intolerance Group (GIG) and verified as natural astaxanthin by the Natural Algae Astaxanthin Association (NAXA).
†Per SPINS data in the natural channel
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
About Nutrex Hawaii
Nutrex Hawaii was founded in Kailua-Kona, Hawaii in 1990. Our founder, Dr. Gerald Cysewski, chose the pristine Kona Coast of Hawaii due to the pure, unpolluted, clean growing location and access to deep ocean water from a depth of 2000 feet. Our 90-acre facility is located in a BioSecure zone, free of all pesticides and herbicides. Direct from the manufacturer, our Hawaiian Spirulina® and BioAstin® Hawaiian Astaxanthin® are guaranteed to be grown and harvested in Hawaii. Learn more at http://www.nutrex-hawaii.com and please follow us on Facebook (Facebook.com/NutrexHawaii), Twitter (@supernutrient) and Instagram (@ITakeBioAstin).
Media Contact: Tanya Khani, Dunn Pellier Media, 310-362-6131, [email protected]


UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management
DeepSeek to Raise AI API Prices as Demand for New Models Surges
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
DHL Q2 Profit Jumps 24% as Express Business Drives Growth
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 



